Navigating the HIV Treatment Frontier: Equipping Managed Care Professionals With Strategies for Innovation, Access, and Adherence

This activity includes HIV credit.

This activity was originally broadcast in conjunction with AMCP 2024.

Program Description

Despite the advances of antiretroviral therapy (ART) in HIV treatment and management, demographic factors, socioeconomic status, and comorbidities still greatly influence treatment outcomes, adherence, and achievement of viral suppression among diverse patient populations. Managed care pharmacists must recognize the unique needs of populations with greater risk factors for HIV transmission as well as heavily treatment-experienced individuals living with HIV who are at increased risk for the development of drug resistance. Expanding access to innovative and more simple ART regimens through formulary management, utilization management programs, value-based contracting, and collaborative care models can reduce treatment burden and improve cost-effectiveness but requires a concerted effort from health care providers, policymakers, advocacy groups, and managed care pharmacists. This program will explore the challenges and opportunities in achieving viral suppression, particularly for patient populations with increased risk factors for HIV transmission and treatment nonadherence. Managed care pharmacists will gain practical insights to promote equitable access to HIV therapies, guidance to optimize economic and health-related outcomes, and best practices for implementation of policies to ensure adherence to ART for people living with HIV.

Target audience: Managed care pharmacists

Type of activity: Application
Release date: May 3, 2024
Expiration date: June 24, 2025

Time to complete activity: 1.5 hours

Learner level: Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the current antiretroviral therapy (ART) landscape and the unmet needs that hinder the achievement of viral suppression in diverse patient populations.
• Apply the latest data and treatment strategies that promote long-term adherence to ART for the prevention and treatment of HIV.
• Investigate managed care policies and best practices to optimize the economic and health-related value of HIV prevention and treatment through patient engagement and adherence support.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-24-125-H02-P. The activity is available for CE credit through June 24, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Heather Free, PharmD, AAHIVP, CPGx

Abby Singleton, PharmD, BCPS

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Adam C. Welch, PharmD, MBA, FAPhA; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms